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ABSTRACT: We live in an era where we expect to be able to 
visit our doctor and obtain a pill to cure any ailment from 
which we suffer. Yet, this is still not the case. Many of the 
current cures are still derived from natural sources although 
new drugs are increasingly the result of intelligent design. In 
this process, X-ray protein crystallography now plays a major 
and effective role in the discovery of new treatments. The 
developments that have made this possible have evolved 
during the past fifty years. The methods for crystallizing 
macromolecules and determining their structures by X-ray 
crystallography have been automated and the speed for X-
ray data acquisition is several orders of magnitude faster. Fif-
ty years ago it took several years to solve a single structure. 
Now, several protein–ligand complexes can be determined 
in single day. High-throughput crystallography is considered 
to be a great asset to the drug discovery process, providing a 
fast way to tailor drug candidates to their targets by analys-
ing their binding mode in detail. Crystallization remains the 
main challenge.
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RESUMEN: Vivimos en una época en la que esperamos ir al 
médico y obtener una pastilla para curar cualquier dolencia que 
padezcamos; por desgracia, esta expectativa no es real. Aunque 
muchos de los remedios en uso provienen de fuentes naturales, 
la mayoría de los nuevos medicamentos son el resultado de la 
investigación científica. En el proceso de diseño y descubrimiento 
de fármacos, la cristalografía de proteínas juega un papel central. 
Los conocimientos que han hecho esto posible han venido 
evolucionando desde hace cincuenta años aproximadamente. 
Los métodos de cristalización de macromoléculas y la 
determinación de sus estructuras a través de la cristalografía de 
rayos X han sido automatizados y miniaturizados y la velocidad 
de la adquisición de datos de difracción ha aumentado en varios 
órdenes de magnitud. Si hace cincuenta años la resolución de una 
sola estructura podría llevar varios años, actualmente se pueden 
determinar las estructuras de varios complejos proteína-ligando 
en un solo día. La cristalografía de alto rendimiento hoy día es 
un gran recurso en el proceso del descubrimiento de fármacos 
pues proporciona una manera rápida y precisa de adaptar los 
fármacos candidatos a las dianas mediante el análisis de su modo 
de unión. La cristalización sigue siendo el principal desafío.
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INTRODUCTION
Protein crystallization pre-dates X-ray crystallogra-
phy. Humans have practised this science since 1840 
(Giegé, 2013), but other organisms have put protein 
crystallization to use much earlier. Bacillus thuring-
iensis, known for its insecticidal properties, produc-
es protein crystals during sporulation. Fifty years ago 
the seminal ideas that would lead to modern protein 
crystallization methods were already in place and as 
it became understood that it was possible to visu-
alize ligands in their binding sites, crystallographic 
pharmaceutical investigations started.
Protein crystals are themselves drugs (Figure 1). 
Insulin is important in the treatment of diabetes, 
and to slow down the release of this hormone it is 
delivered in crystalline form. NPH insulin, a suspen-
sion of crystalline zinc-insulin combined with a pos-
itively charged polypeptide, was created in 1936 
by Nordisk, but the role of zinc, as an additive, to 
induce protein crystallization was not known until 
much later. The insulin crystal story began in 1934 
when Dorothy Hodgkin was offered a small sample 
of crystalline insulin by Robert Robinson (Howard, 
2003). Unfortunately, X-ray crystallography at that 
time could not cope with the complexity of the in-
sulin molecule. She was able to grow better crys-
tals by dialysing concentrated insulin against tap 
water (containing traces of zinc), but failed to do so 
with distilled water. The 3-dimensional structure of 
insulin was eventually determined by X-ray crystal-
lography in her laboratory in 1969 (Crowfood and 
Riley, 1939). Zinc occupies the central position in a 
unit of six insulin molecules (hexamer). The insulin 
hexamer is not a crystallization artefact, but this is 
the form produced and stored in the body. It is in-
active but has long-term stability. The monomer is 
the active form. The hexamer serves to keep the 
highly reactive monomeric insulin protected, yet 
available through hexamer-monomer conversion. 
Insulin can aggregate and form fibrillar interdigitat-
ed β-sheets. This can cause injection amyloidosis, 
and prevents the storage of insulin for long periods 
(Ivanova et al., 2009).
Figure 1. Crystals are drugs. Slow release insulin is designed with the addition of specific bulky hydrophobic 
groups. These insulin crystals are more stable. In addition to zinc stabilization (A), the covalently linked litho-
cholyl group form specific van der Waals and hydrogen-bonding interactions with neighbouring molecules (B) 
to strengthen the crystalline network and slow down dissolution of crystals. Lithocholic acid acylated insulin has 
affinity for circulating serum albumin to ensure slow absorption into the blood stream and prolongation of its 
half-life. The engineered insulin retains its affinity for its insulin receptor. (From PDB entry: 1UZ9; Whittingham 
et al., 2004).
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Amyloid fibril formation and deposition can lead 
to diseases, including spongiform encephalopathies, 
Alzheimer’s and familial amyloidotic polyneuropa-
thies. In familial amyloidotic polyneuropathy (FAP), 
the amyloid fibrils are mostly constituted by variants 
of transthyretin (TTR) (Quintas, Saraiva and Brito, 
1997). Protein instability, leading to aggregation can 
be a problem in protein crystallization for X-ray crys-
tallography, but not always. Transthyretin, previously 
known as prealbumin, is easily crystallized. The first 
crystals were obtained fifty years ago by Purdy et 
al. (1965) and by Haupt and Heide (1966) from 55% 
saturated ammonium sulphate. The crystallization 
of insulin and transthyretin characterise the varia-
tion in solubility of proteins, with respect to the salt 
concentration in which they are bathed (salting-in/
salting-out). Transthyretin is a tetrameric protein in 
dynamic equilibrium with a monomeric form that, 
like insulin, has a tendency to aggregate. To prevent 
FAP, various potential inhibitors are being studied 
to understand the structure–activity relationship 
(SAR) (Nencetti and Orlandini, 2012). The relation-
ship between the chemical or 3D structure of a mol-
ecule and its biological activity. The objective is to 
understand which chemical groups are responsible 
for its effect on the target protein. To achieve such 
an understanding, 222 transthyretin structures, from 
human and other species, complexed and uncom-
plexed have been deposited in the Protein Data Bank 
(PDB) (Berman et al., 2007). The inhibitors stabilize 
the tetrameric form shifting the equilibrium away 
from the amyloidogenic monomer.
Figure 2. Crystals and quaternary structure of transthyretin (TTR) a protein that transports thyroid hormones. The 
morphology of transthyretin crystals is highly variable although the arrangement of the molecules in the lattice 
remains constant (A-C). The crystals shape depends on the rate of growth of the crystals and not on the contacts 
that the molecules make with one another. Four TTR molecules form a tetramer (D) and the tetramer packs 
together with other tetramers always in the same manner. To reliably grow crystals streak seeding can be used. 
The crystals grow in a straight line (E) where the seeds have been deposited by the cat whisker. TTR is studied to 
develop amyloid inhibitors. Such inhibitor binds in the tetramer cavity in two independent binding sites (F). (From 
PDB entry: 4PM1; Ciccone et al., 2015).
ARBOR Vol. 191-772, marzo-abril 2015, a222. ISSN-L: 0210-1963 doi: http://dx.doi.org/10.3989/arbor.2015.772n2008
Protein Crystallizati
on for D
rug D
esign in the Last 50 Years
4
a222
Protein solubility in water is highly variable and 
the salting-in/salting-out concept applies only to 
soluble proteins. Crambin, a polypeptide from the 
seeds of Crambe abyssinica, is not soluble in water. 
It was dissolved in ethanol and crystallized in 1965 
by adding water. It is resistant to denaturing agents 
like 3M urea, and only partially affected by guani-
dinium: It showed some solubility in 8 M guanidine 
hydrochloride (Teeter and Hendrickson, 1979). Urea 
and guanidine are now used to refold proteins ex-
pressed in Escherichia coli and found in inclusion 
bodies (Palmer and Wingfield, 2004), using similar 
concentrations of these agents. High-level expres-
sion of many recombinant proteins in Escherichia 
coli has revolutionized protein crystallization. Highly 
aggregated protein (inclusion bodies) are formed in 
the bacteria cytoplasm when high-level expression 
is induced. It is recovered from cell lysates by low 
speed centrifugation and the protein extracted from 
the washed pellets with guanidine·HCl in a soluble 
but unfolded form that needs to be re-folded into 
its native and biologically active form. Currently the 
PDB contains 105,465 structures, of these 67,321 
(64%) were expressed in Escherichia coli. In the 
1970s, insulin and recombinant DNA technology al-
lows the birth of two biotech companies, Genentech 
and Biogen. The challenge is to insert the DNA se-
quence for human insulin into bacteria and let the 
bacteria produce the hormone.
The use of polyethylene glycol (PEG) to obtain crys-
tals for X-ray data analysis starts in 1975 with deoxy-
hemoglobin crystals diffracting to 3.5 Å. Previously 
it had mainly been used for fractional precipitation 
(Ward et al., 1975). The steric exclusion mechanism 
of this precipitant was correctly identified as being 
similar to that of dextran reported by Torvard Lau-
rent (Laurent, 1963). Size exclusion chromatography, 
using gels, typically made of dextran (Sephadex) and 
of other polymers, has become important as a pro-
tein purification method prior to crystallization. PEG 
is the single most successful precipitant, with cur-
rently 38,976 macromolecular structures deposited 
in the PDB.
While Genentech focuses mainly on proteins and 
antibodies as their products, Vertex Pharmaceuticals 
was founded in 1989 to pioneer an explicit strategy 
of rational drug design rather than combinatorial 
chemistry. The aim is to understand the molecular 
mechanisms of action of natural immunosuppres-
sants, FK506 and rapamycin, that act on peptidyl 
proline isomerase FKBP. The successful structure de-
termination of the FKBP/FK506/calcineurin complex 
encourages others to follow the pathway. Amgen, 
another biotechnology start-up focuses on erythro-
poietin (EPO), a glycoprotein hormone that controls 
red blood cell production. In 1998 they solve the 
structure of the EPO complex with the extracellular 
ligand-binding domain of its receptor (EPO binding 
protein EBP) (Syed et al., 1998), but they were pre-
ceded by a team at The Scripps Research Institute 
(TSRI). The TSRI team succeeds, two years earlier, 
to determine the structure of the complex between 
EBP and an EPO mimetic peptide (EMP) discovered 
by Affymax (Livnah et al., 1996). The synthetic pep-
tide, attached to polyethylene glycol, is approved the 
FDA in 2012, and enters the market in 2013, only to 
be recalled almost immediately, after 3 deaths, as 
0.02% of patients suffer from severe hypersensitivity 
reactions. Successes dominate over failures. Struc-
tural studies have resulted in anti-HIV drugs that 
target the viral reverse transcriptase, integrase and 
protease; and anti-cancer drugs aimed at various ty-
rosine kinases.
NATURAL DRUGS
The immunosuppressant drug, rapamycin, pro-
duced by the bacterium Streptomyces hygroscopicus, 
and FK-506, produced by S. tsukubaensis, are used 
to prevent organ rejection in transplantation. Their 
action prevents activation of T cells and B cells by 
inhibiting the production of interleukin-2 (IL-2). FK-
506 gives the name to a family of FK-binding proteins 
(FKBP). FK-506 binds to FKBP12 thus reducing the 
peptidyl-prolyl isomerase activity of this immunophi-
lin. Most crystals of FKBPs have been obtained only in 
complex with the immunosuppressant drugs.
In “The Billion Dollar Molecule: One Company´s 
quest for the perfect drug”, Barry Werth describes 
the first few years of Vertex in its quest to create 
drugs by rational drug design. Werth renders both 
the science and the intricacies of the business deals 
at Vertex. The narrative offers an insight at a critical 
moment in the history of science when under the im-
pulse of Joshua Boger, a researcher that leaves Merck 
to found a new company, the focus of scientific re-
search also shifts from screening soil samples and 
insect secretions to a new world where proteins and 
their inhibitor complexes can be crystallized and from 
their structure using computing power new drugs 
can be designed. The founding of Vertex’s is vision-
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ary, but the idea that the new drugs would be with-
out side effects because of the precision of the de-
sign, is still to be realised. The book describes Boger’s 
first target molecule, FKBP, important in preventing 
the host’s body from rejecting transplanted organs. 
The contrast between real science and the necessity 
of fund raising sees Boger going out to raise money, 
Vertex’s researchers hunkered down in the laboratory 
benches to isolate and analyse FKBP, in a race against 
a tough team composed of Prof. Stuart L. Schreiber 
at Harvard and Manuel Navia, the crystallographer. 
Manuel’s parents went to the U.S. from Cuba, worked 
really hard and a strong value system that he tried to 
emulate. The advantage of academic science, where 
collaborations are possible, contrasts with the world 
of business where scientists need to hide proprietary 
results instead of presenting them at conferences or 
publishing them open to the criticism of reviewers. 
The book is warmly recommended as a riveting tale 
of human endeavour that shows how scientific antag-
onism can drive discovery. In this historical review we 
are more concerned on how crystallization methods 
have evolved in the past 50 years than in discussing 
academic in contrast to industrial research. 
In crystallization, the inhibitors, substrates, modu-
lators and other ligands, be they other proteins or 
small-molecules are the most important considera-
tion in crystallization (Dale, Oefner and D’Arcy, 2003). 
The various complexes have a different likelihood for 
crystallization and different complexes will be able 
to select a different polymorph (Vera et al., 2013) 
depending on how the ligand is able to change the 
properties of its target. One of the most fundamental 
changes that ligands can cause is the bringing togeth-
er of more that one molecule, in a manner that does 
not occur spontaneously. Even single atoms, like zinc, 
in the case of insulin, can bring together six or more 
protein molecules. This has been recognized to be 
critical in the crystallization of insulin. A single atom, 
oxygen makes the difference between oxy- and de-
oxy- haemoglobin. When oxygen binds to the iron 
complexed at the centre of the plane of the porphy-
rin ring it causes the iron atom to move back. This 
triggers as series of cooperative changes that result 
in a large scale movement of the whole assembly of 
the four molecules that constitute the heamoglobin 
tetramer. The change in a single haemoglobin mol-
ecule is transmitted to the other three monomers 
in the tetramer, so that these too adopt a similar 
conformation in their hemes to facilitate the bind-
ing of oxygen to these sites. A cooperative process 
helps crystallization because all the molecules can 
shift in synchrony from one form to another, avoid-
ing heterogeneity that would make crystallization 
more difficult. In absence of a cooperative process, 
heterogeneity is inevitable and the binding affinity of 
the ligand for the protein becomes important as it 
will determine how many of the protein molecules 
are complexed and how many are not. Higher affinity 
ligands ensure that a higher portion of the protein 
molecules will be complexes. For low affinity ligands 
the ligand is added in excess, up to ten times more 
compared to the protein. This strategy is not effec-
tive to crystallize complexes of two or more proteins. 
In my laboratory we have investigated the use of bi-
functional inhibitors to bring together two proteases 
to change the manner in which crystallization occurs 
(Antoni et al., 2013).
Ideas that the use of PEG instead of salts like am-
monium sulphate would help maintaining complexes 
have been abandoned as it has been realised that at 
high salt concentrations, AS is as effective as PEG.
SYNTHETIC DRUGS
Administration of folic acid (vitamin B9) worsens 
leukemia. This led to the development of folic acid 
analogues, including methotrexate (MTX), to inhibit 
folic acid metabolism. MTX is used in the treat-
ment of cancer and autoimmune diseases. It acts 
by binding to dihydrofolate reductase (DHFR). MTX 
was originally synthesised by an Indian biochemist 
and in 1947. Sidney Farber and co-workers showed 
that the molecule could induce remission in chil-
dren with acute lymphoblastic leukemia. The first 
crystal structures of DHFR with MTX were deter-
mined for bacterial enzymes in 1982. In 1989, the 
crystal structure of the chicken enzyme was solved 
and one year later the first complex of human DHFR 
with the folate and 5-deazafolate were solved. The 
first crystal structure of human DHFR with MTX was 
obtained six years later, in 1995. The enzyme was a 
MTX-resistant mutant with a single point mutation 
in the drug binding pocket. The long delay between 
the demonstration of the effectiveness of the ligand 
and the first crystal structure of the human enzyme 
complex gives an idea of the difficulty of obtain-
ing suitable crystals to carry out drug design. There 
was great interest in DHFR and MTX on behalf of 
pharmaceutical companies. The human DHFR-MTX 
structural studies saw the involvement of research-
ers from Gensia Pharmaceuticals. Agouron Pharma-
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ceuticals was founded in 1978 with the aim to find 
selective inhibititors for DHFR and thymidate syn-
thetase (TS). Hoffmann-La Roche had interests in an-
tibacterial agents that target bacterial dihydrofolate 
reductases. The difficulties associated with protein 
crystallization became evident. Dr. Villafranca from 
Agouron was a co-organizer of the fifth Interna-
tional Conference on the Crystallization of Biological 
Macromolecules (ICCBM-5) in San Diego, in 1993. 
Dr. D’Arcy from Hoffmann-La Roche was there too. 
The National Aeronautics and Space Administration 
(NASA), interested in crystallization in microgravity, 
was a sponsor of the meeting.
Growing crystals in space was impractical, and re-
searchers believed that convection free systems could 
be developed to obtain the same effect on earth. A 
system where silica-gel methods can be used in both 
vapour diffusion sitting drop and liquid-liquid diffu-
sion was proposed as an alternative to micrograv-
ity during the ICCBM-5 conference by Bob Cudney 
(Cudney, Patel and McPherson, 1994). Bob Cudney is 
the current president of Hampton Research, a crys-
tallization supply company. Until the introduction 
of gels, three classical crystallization methods had 
dominated the field. These were batch, dialysis and 
vapour diffusion. The major advances consisted in 
the miniaturization of each of these methods. In the 
batch method, the protein is mixed with the precipi-
tant, nucleation takes place on mixing and the crys-
tals are left to grow. By changing the temperature in 
a controlled manner, the degree of supersaturation 
can be changed. The miniaturization of this method, 
for crystallization under oil suitable for crystallization 
with the IMPAX robot made by Douglas Instruments, 
revived the method that was no longer used (Chay-
en, Shaw Steward and Baldock, 1994). A generaliza-
tion of crystallization with oils was later proposed by 
Naomi Chayen during ICCBM-7 in Granada, Spain, 
in 1998 (Chayen, 1999). Dialysis was miniaturized 
more than forty years ago with microdots of 5-20 µL 
capacity made in plexiglas. New set-ups have been 
proposed using agarose gels to carry out dialysis ex-
periments in capillaries (Thiessen, 1994). Dialysis and 
batch account for only 60 and 766 structures in the 
PDB, respectively, while vapour diffusion counts for 
66,887 entries. José Antonio Gavira has promoted 
the use of free-interface diffusion (Otálora et al., 
2009). Triana Science & Technology, Granada, Spain 
markets a kit to use the technique. The method ac-
counts for only 12 PDB database entries.
DRUGS FROM STRUCTURAL STUDIES
AIDS was first clinically observed in 1981 in the 
United States. In 1983, when the causative agent 
was identified the crystallization field was mature 
to face the challenge to design molecules for anti-
retroviral therapy.
The inhibition of the HIV viral protease is regard-
ed as major success of structure-based drug design. 
The protease inhibitors are highly effective against 
the virus and since the 1990s have been a key com-
ponent of anti-retroviral therapies for AIDS. Nelfi-
navir (Viracept) (Figure 3), a protease inhibitor, was 
developed by Agouron Pharmaceuticals as part of 
a joint venture with Eli Lilly and Company. Saquina-
vir was developed by Roche, Ritonavir (Norvir) by 
AbbVie, Inc. Other companies focused on inhibiting 
HIV’s reverse transcriptase. AZT, a nucleoside-based 
thymidine-analogue inhibitor, works by selectively 
inhibiting transcription. Resistance against nucleo-
tides developed, so non-nucleoside reverse-tran-
scriptase inhibitors were developed. To improve the 
crystals of a clinically relevant double mutant HIV-1 
of reverse transcriptase in complex with ATP and 
the non-nucleoside inhibitor HBY-097 (Das et al., 
2007), streak seeding was used (Stura and Wilson, 
1990). One of the problems with protein crystalli-
zation is that as the crystal growth conditions are 
optimized, nucleation can fail. Seeding is used to 
stimulate nucleation. Various seeding techniques 
can be used (Stura and Wilson, 1991). In microseed-
ing crystals are added to the protein solution before 
full equilibration of the protein precipitant drop. 
This method can fail because the seeds dissolve or 
too many seeds are added. Macroseeding where 
large seeds are added after equilibration, solves 
both problems encountered with microseeding, but 
it is time consuming and manipulation errors can 
also lead to failure.
Streak seeding where crystals are taken from an 
existing crystal with a cat whisker and dispersed in 
a non-equilibrated or equilibrated experiment in 
straight line is fast. Since it is easily repeated if it fails, 
it is a practical method to find the best conditions to 
grow crystals. It can also be used to grow crystals in 
a space group different from that of the seed crys-
tals. This application is called: epitaxial jumps (Stura, 
Charbonnier and Taussig, 1999). The field has still 
many challenges. Over 50% of all modern medicinal 
drug targets are membrane proteins, proteins that 
interact with biological membranes (Figure 4).
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To crystallize these proteins, they must be extract-
ed from the membrane using a detergent, and then 
the crystallization can proceed in a manner analo-
gous to that used for soluble proteins. The problems 
arise when the protein is unhappy in the detergent. 
The in meso method for crystallizing membrane pro-
teins is growing in popularity (Li et al., 2014). 
The method involves both lipids and detergents. 
The lipids are manipulated to generate a continuous 
hard gel called lipid cubic phase (LCP). The protein 
solubilized in detergent is added to the LCP so that 
it can migrate into the lipid phase. The protein incor-
porated into the LCP is dispensed and used in crys-
tallization experiments using the vapour diffusion 
technique as for soluble proteins. The method has in-
creased the number of membrane proteins that have 
been crystallized.
Even if progress has been spectacular in the past 
fifty years, the rapid progress is likely to continue in 
the next fifty years. A crystal ball would be useful to 
predict the future of this science.
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Figure 3. From crystals to drugs. The path towards a drug starts with the conception of an inhibitor (A) which 
ignores the actual three dimensional structure of the compound once in the active site of the enzyme (B). Before 
arriving at a formulation for the patient (C) it passes through a crystal structure. The results are often shown in 
a simplified representation that shows only the secondary structure of the protein (D) and not all the atoms (E). 
HIV protease inhibitors, including Viracept, are one of the great successes of structure-based drug design. (From 
the PDB entry: 1OHR; Kaldor et al., 1997).
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Figure 4. Membrane proteins. Membrane proteins are important targets for drug design. G-protein-coupled 
receptors (GPCR) belong to the bateriorhodopsin (BR) family. They are of great interest to the pharmaceuti-
cal industry because they act as sensors to activate signal transduction pathways and cellular responses. Seven 
transmembrane helices characterize GPCR. BR was the first membrane protein to be crystallized. Initially as two 
dimensional crystals, but now after crystallization using lipidic cubic phases a three dimensional structure at 
atomic resolution has been determined. The transmembrane helices are surrounded by lipids (green) (A). In the 
centre there is a retinol (vitamin A) molecule (cyan). In mammals retinol is transported by retinol binding protein 
which in plasma is found complexed with transthyretin (C). (From PDB entries: 1C3W and 1QAB; Luecke et al., 
1999; Naylor and Newcomer, 1999).
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